Contract Research Organizations (CROs) are emerging as the hotbed for driving innovation and efficiency for pharmaceutical and biotechnology companies and have moved beyond being an outsourcing option to becoming a necessary partner in the value chain. Pharmaceutical and biotechnology companies are continuously seeking to improve competitiveness by reducing costs and decreasing time to market of drugs while the regulatory environment continues to turn more rigorous. As the market continues to expand and inorganic growth emerges as a critical component of market expansion, the trend of continuing to focus more on core expertise rather than adding new services becomes crucial for CROs.
New analysis from Frost & Sullivan titled Global CRO Spending Trends provides detailed revenue forecasts for the CRO markets and key trends in R&D spending and clinical trials. The analysis is available through our CRO Growth Partnership program as well as our Pharmaceuticals & Biotechnology Subscription.
If you are interested in a virtual brochure, detailing this latest analysis, Global CRO Spending Trends, or Frost & Sullivan's subscription content, then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. Upon receipt, an overview will be sent to you by email, and we will then forward this information to our team who will contact you at the above information.
"CROs are increasingly looking at emerging markets as drivers of future growth. The percentage share of clinical trials conducted in North America is expected to undergo a marginal decline despite a healthy overall growth in volume of clinical trials." notes Frost & Sullivan Research Analyst, Barath Shankar. "This signifies the increasing penetration of CROs and also the emergence of emerging markets as hotspots for clinical trials and other areas of outsourcing services."
The CRO Growth Partnership program is a global content solution focused on the CRO sector. Global market coverage by region as well as end-user research provides both supply and demand side information to fulfill the market intelligence needs of companies interested in the contract research industry.
Frost & Sullivan's Pharmaceuticals & Biotechnology practice provides global industry analysis, consulting, customer/end-user and market research information to help our clients with their informational, growth and strategy needs. Subscription clients with Frost & Sullivan's CRO Growth Partnership program gain not only from in-depth research services covering the market, but from vital End-User research.
"Partnering with us enables companies interested in the CRO space to meet their growth and strategic objectives, and information needs," says Frost & Sullivan's North America Pharmaceuticals Industry Manager, Daniel Ruppar. "The ability for clients to have direct access to our global team of analysts as well as market and end user information in this space is something that sets us apart from the competition."
Frost & Sullivan's Pharmaceuticals and Biotechnology Group provides research in the following markets: oncology, cardiovascular, CNS, biotechnology, diabetes/metabolic disease, contract research and manufacturing, infectious disease, respiratory, generics, specialty pharmaceuticals and drug delivery. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
Recent research service titles include: Global CRO Spending Trends, U.S. CRO Markets, Drug Delivery: Snapshots and Highlights, CRO – Competing in North America and APAC (End-user studies).
About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.